Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

                                October 19, 2004
                Date of Report (Date of earliest event reported)

                                 ANTIGENICS INC
             (Exact name of registrant as specified in its charter)

         DELAWARE                      000-29089                  06-1562417
(State or other jurisdiction         (Commission                (IRS Employer
      of incorporation)              File Number)            Identification No.)

       630 Fifth Avenue, Suite 2100
           New York, NY 10111                           10111
 (Address of principal executive offices)            (Zip Code)

              (Registrant's telephone number, including area code)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR

[ ] Soliciting material pursuant to Rule  14a-12 under the Exchange  Act (17 CFR

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

Item 2.02      Results of Operations and Financial Condition

               On October 19, 2004,  Antigenics  Inc.  announced  its  financial
               results for the quarter ended  September 30, 2004.  The full text
               of the press release issued in connection  with the  announcement
               is being furnished as Exhibit 99.1 to this current report on Form

Item 9.01      Financial Statements and Exhibits

        (c) Exhibits:

               99.1     Press Release dated October 19, 2004


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                                 ANTIGENICS INC.

Date: October 19, 2004
                                                          By:  /s/ Garo H. Armen

                                                            Garo H. Armen, Ph.D.
                                            Chairman and Chief Executive Officer


The following designated exhibits are filed herewith:


99.1                       Press Release dated October 19, 2004